Common Contracts
2 similar Investor Rights Agreement contracts by Aeglea BioTherapeutics, Inc.
EX-4 4 filename4.htm AEGLEA BIOTHERAPEUTICS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT March 10, 2015 Page (CONTINUED) Page AEGLEA BIOTHERPEUTICS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • May 5th, 2020 • Delaware
This Amended and Restated Investor Rights Agreement (the “Agreement”) is entered into as of this 10th day of March 2015, by and among Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and each holder of the Company’s Series A Preferred Stock, $0.0001 par value per share (“Series A Preferred Stock”) and Series B Preferred Stock, $0.0001 par value per share (“Series B Preferred Stock”, referred to herein collectively with the Series A Preferred Stock as the “Preferred Stock”) listed on Schedule A (together with any subsequent investors, or transferees, who become parties hereto as “Investors” pursuant to Section 6.1 below, the “Investors”).
AEGLEA BIOTHERAPEUTICS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT March 10, 2015Investor Rights Agreement • June 16th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Delaware
This Amended and Restated Investor Rights Agreement (the “Agreement”) is entered into as of this 10th day of March 2015, by and among Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and each holder of the Company’s Series A Preferred Stock, $0.0001 par value per share (“Series A Preferred Stock”) and Series B Preferred Stock, $0.0001 par value per share (“Series B Preferred Stock”, referred to herein collectively with the Series A Preferred Stock as the “Preferred Stock”) listed on Schedule A (together with any subsequent investors, or transferees, who become parties hereto as “Investors” pursuant to Section 6.1 below, the “Investors”).
